Background {#Sec1}
==========

Feeding human milk has a lot of beneficial effects on preterm and term newborn infants. It contains immunoglobulins and cytokines and therefore offers protection against infections \[[@CR1]--[@CR3]\]. Besides, the ingestion of maternal milk reduces the incidence of necrotizing enterocolitis \[[@CR4], [@CR5]\], retinopathy of prematurity \[[@CR5]\] and diabetes type 1 and 2, as well as obesity in later life \[[@CR6], [@CR7]\]. Furthermore, it is associated with improved neurocognitive and psychomotor development \[[@CR8]\]. Therefore, mother's milk is considered the optimal nutritional source for preterm infants \[[@CR9]\]. However, human milk does not meet the high nutrient needs of preterm infants, hence requires supplementation with multicomponent fortifiers \[[@CR10]\]. Nevertheless, many preterm infants show early postnatal growth retardation despite having been fed fortified human milk \[[@CR11]\].

In general, an average composition of breast milk is assumed and fortifiers are added in a standardized manner, but this assumption is rarely appropriate \[[@CR12]\], because human milk is a biological product with considerable intra- and inter-individual variation of its macro- and micronutrient content, particularly protein \[[@CR13]\].

To ensure an optimal supplementation with protein in the daily neonatal intensive care unit (NICU) routine, it is necessary to establish a feasible method to assess the individual protein supply and, ideally, protein availability for growth in very preterm infants.

Frequent measurements of the individual breast milk macronutrient content using a milk analyzer (mid-infrared spectroscopy) is an easy and valid method to assess macronutrient supply \[[@CR14]\]. Nevertheless, due to the immaturity of the gastrointestinal system of a preterm infant and the individual intestinal microbiome the calculation of actual macronutrient supply might not reflect the effectively absorbed amount of protein, fat and energy ('actual intake'). Our concept of the interaction of actual protein intake and growth on plasma (PUC) and urinary urea concentrations (UUC) is illustrated in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Concept of the interaction of actual protein intake and growth on plasma and urinary urea concentrations

The PUC represents amino acid oxidation and therefore offers information about availability of protein after absorption and incorporation for growth, provided that fluid intake, kidney function and quality of the nutritional protein remain unchanged. However, associated blood samples are painful, contribute to blood loss and carry the risk for additional complications. In contrast, urine can be collected non-invasively and painlessly, and is frequently collected to guide calcium and phosphate supplementation in preterm infants \[[@CR15]\]. Because the UUC may be confounded by fluid homeostasis, normalization of urinary urea for the creatinine excretion as the urinary-urea-creatinine-ratio (UUCR) may be appropriate.

The aim of this study was to determine 1) the impact of increased enteral protein intake on PUC and UUCR in very preterm infants and 2) if the UUCR represent PUCs and actual enteral protein supply in this population.

Methods {#Sec2}
=======

Detailed information on the underlying randomized controlled trial has been previously reported \[[@CR16]\]; in short**:**

From October 2012 to October 2014, this partially blinded randomized controlled trial was conducted at the department of neonatology at Tübingen university children's hospital, Germany. The Institutional Review Board approved the protocol and written informed parental consent was obtained. The trial was registered with Clinicaltrials.gov as NCT01773902.

The primary objective of the randomized controlled trial was to evaluate the effects of different target levels of enteral protein supplementation on growth in predominantly human milk fed very preterm infants \[[@CR16]\], where no significant difference regarding the growth velocity (g/kg/d) from birth to end of intervention was shown. Both groups achieved near-fetal growth-rates. Secondary objectives of this trial were analysis of UUCR and PUC.

Participants {#Sec3}
------------

Sixty preterm infants born at our hospital within the above time frame, and with gestational age \< 32 weeks at birth and weight \< 1500 g were included. Main exclusion criteria were major congenital or chromosomal abnormalities.

Intervention {#Sec4}
------------

Infants were randomly assigned in proportions of 2/1/1 to one of three parallel treatment groups (after reaching 100 ml/kg enteral nutrition per day and informed consent was given) including:

1\) a lower-protein group (LPG) (standardized fortification adding 5 g/100 ml of the commercially available multicomponent fortifier FM 85**®** (Nestlé Nutrition, Frankfurt, Germany; the standard fortifier in our unit, ingredients shown in Table [1](#Tab1){ref-type="table"}) resulting in supplementation of 1 g protein/100 ml);Table 1Ingredients of the multicomponent fortifiers5 g BEBA FM 855 g Study fortifier 10.01.DE.INF74 kJ / 18 kcal90 kJ / 22 kcalProtein1,0 g1,8 gTotal carbohydrates (including:)3,3 g1,8 glactose0 g0 gmaltodextrin3,2 g1,8 gOther carbohydrates0,1 g0 gTotal lipids (incuding:)0,02 g0,87 gdocosahexaenic acid (DHA)0,0075 garachidonic acid (AA)0,0006 gSodium20 mg33 mgPotassium42 mg83 mgChloride17 mg29 mgCalcium75 mg94 mgPhosphor45 mg56 mgMagnesium2 mg5 mgIron1,3 mg0,94 mgCopper0,04 mg0 mgZinc0,8 mg0 mgIodine15 μg19 μgSelenium1,5 μg4,25 μgVitamin A0,15 mg0,5 mgVitamin D2,5 μg5 μgVitamin E2,0 mg5 mgVitamin K4,0 μg10 μgVitamin C10 mg25 mgVitamin B10,05 mg0,19 mgVitamin B20,10 mg0,25 mgVitamin B60,05 mg0,16 mgFolic Acid40 μg50 μgVitamin B50,4 mg0,88 mgVitamin B120,1 μg0,25 μgBiotin3 μg4 μg

2\) a higher-protein group (HPG) which comprised subgroups:

2a) with standardized higher protein supplementation using 5 g/100 ml of an investigational multicomponent fortifier. The study fortifier administered to group 2a) contained 1.8 g protein/5 g fortifier (10.01.DE.INF, Nestlé Nutrition, Frankfurt, Germany, ingredients shown in Table [1](#Tab1){ref-type="table"}).

2b) individually adjusted fortification based on the individual human milk macronutrient content on top of standardized fortification as in group 1.

In all three study groups, multicomponent fortifier was added at a fixed dose of 2.5 g/100 ml breast milk at enteral intakes between 100 and 149 ml/kg/d and at 5 g/100 ml breast milk once ≥150 ml/kg/d of enteral feeds had been reached and always thereafter.

In infants randomized to individual fortification (group 2b), the protein dosage was adjusted according to breast milk content aiming for 4.5 g/kg/d of enteral protein if the weight was \< 1500 g or 4.0 g/kg/d of enteral protein if the weight was \> 1500 g according to recommendations of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition \[[@CR17]\]. Moreover, fat was supplemented to ensure a cumulative fat intake \> 4.8 g/kg/d. Aptamil Eiweiß+®, (Milupa, Friedrichsdorf, Germany) was used as an additional protein source in individually supplemented infants and a generic medium-chain triglyceride oil (Oleum neutrale) was used as an additional source of enteral fat. In the following, group 2a (mean protein intake 4,38 g/kg/d) and 2b (mean protein intake 4,12 g/kg/d) were combined (HPG; mean protein intake 4,30 g/kg/d) for further investigations.

Measurement of serum and urine urea {#Sec5}
-----------------------------------

According to the study protocol, venous blood samples to measure PUC were scheduled on day 14 (±2) and day 28 (±4) after randomization, but had to be re-scheduled until clinical indication arose to avoid study-driven needle-sticks, which resulted in an earlier collection of BS 1. BS 1 was taken on day 9 (7--10) after randomization, BS 2 on day 27 (24--32). Since UUCs were measured weekly, the closest urine sample (BS max. + / - 3 days) was matched to each blood sample. For BS1 sample size was 54; for BS2 sample size was 41 (available serum-urine-urea-pair).

To take the individual fluid turnover of the preterm infants into account UUCs are shown as urinary urea to urinary creatinine ratio (urea concentration (mg/dl) /creatinine concentration (mg/dl) of the same urine sample) (UUCR).

Every week the urinary urea and creatinine concentrations were measured from clinically indicated spot urine samples used for guidance of calcium and phosphorus supplementation as described in \[[@CR15]\]. Urine was collected non-invasively with an absorbent fleece placed in the diaper.

Biochemical analyses {#Sec6}
--------------------

Determination of PUC and UUC was performed on the ADVIA XPT clinical chemistry analyzer (Siemens Healtheneers, Eschborn, Germany). Internal and external quality controls were always within the allowed ranges. The inter assay coefficient of variation was \< 2.5% for plasma and \< 4% for urine.

Actual daily protein supply {#Sec7}
---------------------------

The median actual daily protein supply (based on mother's milk protein content (measured twice a week with a human milk analyzer (Miris, Uppsala, Sweden; infrared spectroscopy; calibration was carried out once a day as recommended by the manufacturer using a check solution); formula's protein content, protein content of the fortifier and parenteral amino acid supply) was calculated for the 5 days prior to the respective blood sample to ensure that variations due to clinical nutrition restriction/ lack of mother's milk were taken into account.

Single samples of breast milk were used to measure macronutrient content as the mean of three individual measurements.

Statistical analyses {#Sec8}
--------------------

Statistical analyses were performed using Microsoft Excel and the statistic software JMP. Data was tested with non-parametric Wilcoxon-Test and Spearman's rank correlation coefficient (rho) was used for analysis of correlation, since not all data showed normal distribution. Results are shown as median and p25-p75.

Results {#Sec9}
=======

There were no differences in birth weight, gestational age at birth, gender or length of hospital stay between the LPG and the HPG \[[@CR16]\], no statistic differences regarding the comorbidities due to early preterm birth between the two groups were shown (Table [2](#Tab2){ref-type="table"}). The HPG had a significant higher protein supply while no difference in median energy supply was shown considering the time from birth to end of intervention and no difference in weight gain was shown (Table [3](#Tab3){ref-type="table"}).Table 2Comparison of the comorbidities of LPG and HPGLPGHPG*p*-valueNEC (≥ Bell stage 2A)0(0)0(0)1PDA therapy (indomethacin or ibuprofen)4(13)3(10)1BPD (physiological definition^a^)0(0)2(7)0,49ROP^b^/^c^0(0)1(3)1IVH^d^3(10)0(0)0,24PVL / intra-parenchymal bleeding0(0) / 0(0)0(0) / 0(0)1 / 1Corticosteroid administration inhaled / systemic^e^0(0) / 1(3)5(17) / 1(3)0,05 / 1^a^moderate or severe BPD indicated by need for positive pressure respiratory support or supplemental oxygen at a postmenstrual age of 36 weeks to maintain an SpO2 \> 90%, verified by a room air test where indicated^b^no ophthalmologic examination in 6 patients^c^max. Stage of ROP in all participants: stage I^d^max. Grade of IVH in all participants: grade I^e^budesonide inhalation, systemic supply of hydrocortisone (no patient received dexamethasone)Table 3Patient details lower-protein group vs. higher-protein group, data shown as number n (%), respectively median (p25-p75), or \*mean (±SD)Lower-protein groupHigher-protein group*p*-valueSex female19(63)14(47)0,3Gestational age in weeks30,0(29,0--31,1)29,7(27,9--31,0)0,2Birth weight in g1215(1065--1393)1193(984--1326)0,61Day of randomisation\
in days after birth7(6--7)7(6--8)0,75Length of hospital stay52(42--65)52(37--70)0,6Mean protein supply in g/kg/d (birth to end of intervention)3,82(3,59--3,93)4,30(4,11--4,43)\< 0,0001Mean energy supply in kcal/kg/d (birth to end of intervention)136(133--143)137(135--147)0,62Weight gain in g/kg/d (birth to end of intervention, primary outcome of the underlying study)\*16,25 (±2,22)\*16,02 (±2,48)\*0,71

In comparison to the LPG, the HPG had also a significantly higher mean actual daily protein supply 5 days before blood sampling (Fig. [2](#Fig2){ref-type="fig"}); accordingly, in both samples higher PUC in the HPG were detected (Fig. [3](#Fig3){ref-type="fig"}).Fig. 2Protein intake 5 days before blood samples (BS) were taken **a** BS1: lower-protein group (4.02 (3.72--4.42)) vs. higher-protein group (4.69 (4.34--5.01)) *p* \< 0.001; **b** BS2 - lower protein group (3.49 (3.30--3.99)) vs. higher-protein group (4.19 (3.92--4.38)) *p* \< 0.0001Fig. 3Plasma urea (PU) concentrations (mg/dl) -- **a** Blood sample (BS) 1 lower-protein group 23.9 (17.7--29.6)) vs. higher-protein group 30.6 (22.8--37.6) *p* = 0.03; **b** BS2 lower-protein group 12.9 (11.4--16.3) vs. higher-protein group 19.2 (15.0--21.9) *p* = 0.0008

The UUCR in the whole cohort ranged from 3.7 to 87.1 (median: 30.0) with a 2.5 Percentile of 9.3.

The UUCRs in both groups were similar in week 2 of life, but significantly higher in the HPG in week 3, as well as in weeks 5 through 7, with a trend to higher UUCRs in the HPG in week 4 (*p* = 0.08) (Table [4](#Tab4){ref-type="table"}).Table 4Urinary urea-creatinine-ratio in the lower protein group versus high protein group in week two to seven after birth, showing significant difference in week 3 and from week 5 to week 7WeeksLower-protein group\
urinary urea-creatinine-ratioHigher-protein group\
urinary urea-creatinine-ratio*p*-value238,0 (24,1--52,7)43,3 (30,2--49,5)0.77325,8 (16,9--41,1)39,9 (33,5--51,0)0.0019426,2 (20,7--31,3)30,9 (24,4--46,5)0.086521,0 (14,9--26,0)30,7 (26,2--38,5)0.0024625,3 (17,4--29,6)33,7 (25,1--42,2)0.029716,3 (12,1--30,8)34,0 (27,8--52,0)0.0083

UUCRs and PUCs showed a highly significant positive correlation when all samples were compared (*p* \< 0.0001), with ρ = 0.72 (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Plasma urea concentration in mg/dl and Urinary urea-creatinine-ratio (UUCR) show highly significant positive correlation (*p* \< 0.0001), *ρ* = 0.72; y = 11.28407 + 0.9221688\*x

In addition, median actual daily protein intake in the last 5 days before BS was calculated and PUC as well as the matched UUCR samples showed a highly significant positive correlation (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5Actual protein intake (5d before blood sample (BS)) and **a** Plasma urea concentration (*p* \< 0.0001; ρ = 0.59); y = − 25.8499 + 11.644884\*x and **b** Urinary urea-creatinine ratio (UUCR) (*p* \< 0.0001; *ρ* = 0.47) showed highly significant positive correlation; y = − 14.80586 + 11.401612\*x

No correlation of median daily growth rate during 5 days prior to BS was observed with PUC (*p* = 0.7; *ρ* = − 0.03) and UCC (*p* = 0.56; ρ = − 0.04) in this generally well-thriving cohort (Difference of weight-SDS between end of intervention and birth were LPG: 0.26 (− 0.18--0.60) and HPG: 0.13 (− 0.11--0.60), respectively).

Discussion {#Sec10}
==========

Inadequate postnatal enteral protein supply (and absorption, hence intake) may contribute to early postnatal growth failure of preterm infants \[[@CR18]\], which may be associated with poor neurocognitive outcome in later life \[[@CR19]\]. In cases of intrauterine growth retardation, reduced plasma amino acid concentrations were observed in cord blood samples during the third trimester \[[@CR20]--[@CR22]\].

At the contrary, an excess in protein supply may no longer improve growth \[[@CR16], [@CR23]\] and may theoretically also have adverse effects and should therefore be avoided.

Beyond defining the actual protein supply to a preterm infant, the immaturity of the gastrointestinal tract (as well as the individual microbiome) may impair individual absorption of administered protein. Therefore, further information is required to estimate whether the actual protein intake is adequate, i.e. to determine whether additional protein supply may help to optimize growth or is inadequate because the infant already oxidizes excessively administered protein.

High enteral protein intake results in higher blood urea nitrogen levels in preterm infants, which can be used as a guidance to estimate optimal protein supply in enterally fed preterm infants. In addition, an excess of protein leads to higher PUCs and therefore high PUCs might identify a surplus of protein \[[@CR16], [@CR23]\].

Our investigations show a highly significant correlation between PUCs and UUCRs and in addition a highly significant positive correlation between UUCRs and PUCs and actual protein intake in fairly stable fully enterally fed very preterm infants.

Measuring UUCs and its normalization for creatinine excretion as UUCRs, as indicator (surrogate parameter) of amino acid oxidation, would be an easy, non-invasive way to estimate oxidation of surplus protein (as result of enteral protein supply and absorption and growth) in preterm infants. Measuring UUCs is already used in older children and adults to evaluate protein turn-over and intake, e.g. in the context of renal failure. In the late 1960's, a decrease in UUCs during periods of prolonged starvation was detected in adults \[[@CR24]\], and therefore UUCR could become a marker for protein malnutrition in preterm infants, too. Polberger et al. showed in 1990 that low protein intakes result in low serum and urinary urea concentrations, and vice versa \[[@CR25]\]. Despite a lack of good correlation between parenteral supply of protein and blood urea nitrogen levels in unstable preterm infants during the first days of life \[[@CR26]\], Roggero et al. identified blood urea nitrogen as a potential marker of protein intake in low-birth-weight preterm infants on full enteral feeds \[[@CR27]\]. The major advantage of assessing UUCRs is that urine is regularly disposed with the diapers; non-invasive collection of urine is painless and does not bear any risk for the infant. In our institution, urine collection is performed every week to assess calcium and phosphate metabolism in very low birth weight infants \[[@CR15]\], so routine measurements of UUCR can be easily established. Considering that preterm infants continuously receive enteral nutrition every 2--3 h, spot urine sampling is considered to be sufficiently precise regarding the mineral homeostasis in a stable preterm infant \[[@CR28]\] and may be sufficient to assess UUCRs as well.

Patients from this study with an actual protein supply of 4.0--4.5 g/kg/d during the 5 days prior to BS, standardized feeding regimens and near-optimal growth along their intrauterine birth trajectories \[[@CR16]\], had UUCRs ranging from 3.7 to 84.7 (min; max); median: 36.1. This wide range indicates that variability of protein oxidation and urea elimination is high, even if protein supply is adequate, probably due to variability in protein absorption, growth rate, need for protein oxidation for gluconeogenesis and energy metabolism, as well as kidney function. Consequently, confounding factors as well as mediators and modifiers need to be considered when interpreting UUCRs (Fig. [1](#Fig1){ref-type="fig"}).

In this well thriving cohort (SDS-difference for weight between birth and end of intervention 0.18 (− 0.165--0.59)) \[[@CR16]\] with adequate actual protein supply 4.0 (3.8--4.3) g/kg/d the 2.5 percentile of UUCR was 9.3. Lower UUCRs (\< 9 mg/mg) may indicate a low protein availability. Hence in preterm infants with inadequate weight gain and UUCRs \< 9 insufficient protein availability should be considered as cause for growth failure.

Nevertheless, further investigations addressing the before mentioned confounding factors and mediators in a larger population are needed to determine reliable cut-off values and to establish an algorithm based on UUCR and confounding factors to indicate adequacy of protein intake in clinical routine.

Limitations and strengths of the study {#Sec11}
--------------------------------------

In this randomized controlled study, the primary goal was to determine the effect of two levels of protein supply on weight gain. Nitrogen intake and balance weren't measured directly and the study population lacks infants with clearly insufficient protein intake. At the contrary, actual protein intakes, weight gain and longitudinal growth, PUCs and UCCs (and respectively UUCRs) were assessed prospectively, and the whole cohort showed near-intrauterine weight gain throughout the study.

Conclusion {#Sec12}
==========

In very preterm infants, determination of urinary urea/urinary creatinine ratios (UUCR) is a promising approach to estimate adequacy of protein supply non-invasively, since urinary urea/urinary creatinine ratios show highly positive correlation with plasma urea concentrations and actual protein supply.
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